FLT3LG and neoplasm: Levels of FMS-like tyrosine kinase 3 ligand (FLT-3L), implicated in anti-tumor activity via mobilization of dendritic cells (DCs) [16], were higher in CB patients compared to NCB (Fig. 1a) both at baseline and on treatment.